VHL and renal cell carcinoma: Our current research efforts pursue this drug repurposing at three levels: (a) the mechanistic level, by interrogating the functional exchanges between anoikis signaling and phenotypic EMT within the kidney TME to define novel mechanisms of action; (b) the translational level by directly examing precision combination therapies in pre-clinical models of RCC with and without VHL mutations; and (c).